Resveratrol has protective effects against airway remodeling and airway hyperreactivity in a murine model of allergic airways disease

Simon Guy Royce, William Dang, Gao Yuan Yuan, Jenny Tran, Assam El-Osta, Tom Karagiannis, Mimi LK Tang

Research output: Contribution to journalArticleResearchpeer-review

Abstract

BACKGROUND: New therapies for asthma which can address three main interrelated features of the disease, airway inflammation, airway remodeling and airway hyperreactivity, are urgently required. Resveratrol, a well known red wine polyphenol has received much attention due to its potential anti-aging properties. This compound is an agonist of silent information regulator two histone deacetylases and has many effects that are relevant to key aspects of the pathophysiology of asthma including inflammation, cell proliferation and fibrosis. Therefore, resveratrol may offer a novel asthma therapy that simultaneously inhibits airway inflammation, and airway remodeling which are the main contributors to airway hyperreactivity and irreversible lung function loss. METHODS: We evaluated the effects of systemic resveratrol treatment in a murine model of chronic allergic airways disease which displays most of the clinicopathological features of severe human asthma. Wild-type Balb/c mice with allergic airways disease were treated with 12.5 mg/kg resveratrol or vehicle control. Airway inflammation was assessed by bronchoalveolar lavage fluid cell counts and histological examination of lung tissue sections. Further, remodeling was assessed by morphometric analysis and lung function was assessed by invasive plethysmography measurement of airway resistance and dynamic compliance. RESULTS: Mice treated with resveratrol exhibited reduced tissue inflammation as compared to vehicle treated mice (p < 0.05). Additionally, resveratrol treatment resulted in reduced subepithelial collagen deposition as compared to vehicle treated mice (p < 0.05) and attenuated airway hyperreactivity (p < 0.05). Conclusions: These novel findings demonstrate that treatment with resveratrol can reduce structural airway remodeling changes and hyperreactivity. This has important implications for the development of new therapeutic approaches to asthma.
Original languageEnglish
Article number7134
Number of pages10
JournalPathobiology of Aging & Age-related Diseases
Volume1
DOIs
Publication statusPublished - 2011

Keywords

  • resveratrol
  • asthma
  • airway remodeling
  • allergic airways disease
  • fibrosis

Cite this

@article{a07742e855c9477bb9c4095101e80532,
title = "Resveratrol has protective effects against airway remodeling and airway hyperreactivity in a murine model of allergic airways disease",
abstract = "BACKGROUND: New therapies for asthma which can address three main interrelated features of the disease, airway inflammation, airway remodeling and airway hyperreactivity, are urgently required. Resveratrol, a well known red wine polyphenol has received much attention due to its potential anti-aging properties. This compound is an agonist of silent information regulator two histone deacetylases and has many effects that are relevant to key aspects of the pathophysiology of asthma including inflammation, cell proliferation and fibrosis. Therefore, resveratrol may offer a novel asthma therapy that simultaneously inhibits airway inflammation, and airway remodeling which are the main contributors to airway hyperreactivity and irreversible lung function loss. METHODS: We evaluated the effects of systemic resveratrol treatment in a murine model of chronic allergic airways disease which displays most of the clinicopathological features of severe human asthma. Wild-type Balb/c mice with allergic airways disease were treated with 12.5 mg/kg resveratrol or vehicle control. Airway inflammation was assessed by bronchoalveolar lavage fluid cell counts and histological examination of lung tissue sections. Further, remodeling was assessed by morphometric analysis and lung function was assessed by invasive plethysmography measurement of airway resistance and dynamic compliance. RESULTS: Mice treated with resveratrol exhibited reduced tissue inflammation as compared to vehicle treated mice (p < 0.05). Additionally, resveratrol treatment resulted in reduced subepithelial collagen deposition as compared to vehicle treated mice (p < 0.05) and attenuated airway hyperreactivity (p < 0.05). Conclusions: These novel findings demonstrate that treatment with resveratrol can reduce structural airway remodeling changes and hyperreactivity. This has important implications for the development of new therapeutic approaches to asthma.",
keywords = "resveratrol, asthma, airway remodeling, allergic airways disease, fibrosis",
author = "Royce, {Simon Guy} and William Dang and Yuan, {Gao Yuan} and Jenny Tran and Assam El-Osta and Tom Karagiannis and Tang, {Mimi LK}",
year = "2011",
doi = "10.3402/pba.v1i0.7134",
language = "English",
volume = "1",
journal = "Pathobiology of Aging & Age-related Diseases",
issn = "2001-0001",
publisher = "Co-Action Publishing",

}

Resveratrol has protective effects against airway remodeling and airway hyperreactivity in a murine model of allergic airways disease. / Royce, Simon Guy; Dang, William; Yuan, Gao Yuan; Tran, Jenny; El-Osta, Assam; Karagiannis, Tom; Tang, Mimi LK.

In: Pathobiology of Aging & Age-related Diseases, Vol. 1, 7134, 2011.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Resveratrol has protective effects against airway remodeling and airway hyperreactivity in a murine model of allergic airways disease

AU - Royce, Simon Guy

AU - Dang, William

AU - Yuan, Gao Yuan

AU - Tran, Jenny

AU - El-Osta, Assam

AU - Karagiannis, Tom

AU - Tang, Mimi LK

PY - 2011

Y1 - 2011

N2 - BACKGROUND: New therapies for asthma which can address three main interrelated features of the disease, airway inflammation, airway remodeling and airway hyperreactivity, are urgently required. Resveratrol, a well known red wine polyphenol has received much attention due to its potential anti-aging properties. This compound is an agonist of silent information regulator two histone deacetylases and has many effects that are relevant to key aspects of the pathophysiology of asthma including inflammation, cell proliferation and fibrosis. Therefore, resveratrol may offer a novel asthma therapy that simultaneously inhibits airway inflammation, and airway remodeling which are the main contributors to airway hyperreactivity and irreversible lung function loss. METHODS: We evaluated the effects of systemic resveratrol treatment in a murine model of chronic allergic airways disease which displays most of the clinicopathological features of severe human asthma. Wild-type Balb/c mice with allergic airways disease were treated with 12.5 mg/kg resveratrol or vehicle control. Airway inflammation was assessed by bronchoalveolar lavage fluid cell counts and histological examination of lung tissue sections. Further, remodeling was assessed by morphometric analysis and lung function was assessed by invasive plethysmography measurement of airway resistance and dynamic compliance. RESULTS: Mice treated with resveratrol exhibited reduced tissue inflammation as compared to vehicle treated mice (p < 0.05). Additionally, resveratrol treatment resulted in reduced subepithelial collagen deposition as compared to vehicle treated mice (p < 0.05) and attenuated airway hyperreactivity (p < 0.05). Conclusions: These novel findings demonstrate that treatment with resveratrol can reduce structural airway remodeling changes and hyperreactivity. This has important implications for the development of new therapeutic approaches to asthma.

AB - BACKGROUND: New therapies for asthma which can address three main interrelated features of the disease, airway inflammation, airway remodeling and airway hyperreactivity, are urgently required. Resveratrol, a well known red wine polyphenol has received much attention due to its potential anti-aging properties. This compound is an agonist of silent information regulator two histone deacetylases and has many effects that are relevant to key aspects of the pathophysiology of asthma including inflammation, cell proliferation and fibrosis. Therefore, resveratrol may offer a novel asthma therapy that simultaneously inhibits airway inflammation, and airway remodeling which are the main contributors to airway hyperreactivity and irreversible lung function loss. METHODS: We evaluated the effects of systemic resveratrol treatment in a murine model of chronic allergic airways disease which displays most of the clinicopathological features of severe human asthma. Wild-type Balb/c mice with allergic airways disease were treated with 12.5 mg/kg resveratrol or vehicle control. Airway inflammation was assessed by bronchoalveolar lavage fluid cell counts and histological examination of lung tissue sections. Further, remodeling was assessed by morphometric analysis and lung function was assessed by invasive plethysmography measurement of airway resistance and dynamic compliance. RESULTS: Mice treated with resveratrol exhibited reduced tissue inflammation as compared to vehicle treated mice (p < 0.05). Additionally, resveratrol treatment resulted in reduced subepithelial collagen deposition as compared to vehicle treated mice (p < 0.05) and attenuated airway hyperreactivity (p < 0.05). Conclusions: These novel findings demonstrate that treatment with resveratrol can reduce structural airway remodeling changes and hyperreactivity. This has important implications for the development of new therapeutic approaches to asthma.

KW - resveratrol

KW - asthma

KW - airway remodeling

KW - allergic airways disease

KW - fibrosis

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417665/

U2 - 10.3402/pba.v1i0.7134

DO - 10.3402/pba.v1i0.7134

M3 - Article

VL - 1

JO - Pathobiology of Aging & Age-related Diseases

JF - Pathobiology of Aging & Age-related Diseases

SN - 2001-0001

M1 - 7134

ER -